Realm Therapeutics PLC Stock Price, News & Analysis (LON:RLM)

GBX 37.50 0.00 (0.00 %)
(As of 11/24/2017 04:00 PM ET)
Previous CloseGBX 37.50
Today's RangeGBX 37.50 - GBX 37.50
52-Week RangeGBX 26.50 - GBX 45
VolumeN/A
Average Volume46,108 shs
Market Capitalization£35.11 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Realm Therapeutics PLC (LON:RLM)

Realm Therapeutics PLC logoRealm Therapeutics plc, formerly PuriCore plc, is a biopharmaceutical company. The Company is focused on leveraging its immunomodulatory technology to protect and improve the health of adults and children. The Company has initiated drug development programs based on its hypochlorous acid technology. The Company is engaged in the development of small molecule therapies with potential application for the treatment of diseases in a number of therapeutic areas, and an initial focus in dermatology and ophthalmology. The Company has developed proprietary formulations of its technology, with anti-inflammatory and immunomodulatory benefits. Its pipeline of products include PR013 and PR022, which are in Phase I. PR013 is indicated for allergic conjunctivitis and PR022 is indicated for atopic dermatitis. Realm Therapeutics, Inc. is a subsidiary of the Company.

Receive RLM News and Ratings via Email

Sign-up to receive the latest news and ratings for RLM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolLON:RLM
  • Previous Symbol: LON:PURI
  • CUSIPN/A
    Phone+1-484-3212700

    Debt

    Debt-to-Equity RatioN/A
    Current RatioN/A
    Quick RatioN/A

    Price-To-Earnings

    Trailing P/E RatioN/A
    Forward P/E RatioN/A
    P/E GrowthN/A

    Sales & Book Value

    Annual SalesN/A
    Price / SalesN/A
    Cash FlowN/A
    Price / CashN/A
    Book ValueN/A
    Price / BookN/A

    Profitability

    Trailing EPSGBX (0.13)
    Net IncomeN/A
    Net Margins-635.44%
    Return on Equity-45.72%
    Return on Assets-40.33%

    Miscellaneous

    EmployeesN/A
    Outstanding Shares116,560,000

    Frequently Asked Questions for Realm Therapeutics PLC (LON:RLM)

    What is Realm Therapeutics PLC's stock symbol?

    Realm Therapeutics PLC trades on the London Stock Exchange (LON) under the ticker symbol "RLM."

    Who are some of Realm Therapeutics PLC's key competitors?

    Who are Realm Therapeutics PLC's key executives?

    Realm Therapeutics PLC's management team includes the folowing people:

    • John Alex Martin, Chief Executive Officer, Executive Director (Age 49)
    • Marella Thorell, Chief Financial Officer, Finance Director, Chief Operating Officer, Executive Director, Company Secretary (Age 49)
    • Charles A. E. Spicer, Non-Executive Chairman (Age 50)
    • Ivan Philip Gergel M.D., Non-Executive Director (Age 56)
    • Balkrishan Gill, Non-Executive Director of the Board (Age 51)
    • Joseph William Birkett, Senior Independent Non-Executive Director (Age 67)

    How do I buy Realm Therapeutics PLC stock?

    Shares of Realm Therapeutics PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

    What is Realm Therapeutics PLC's stock price today?

    One share of Realm Therapeutics PLC stock can currently be purchased for approximately GBX 37.50.

    How big of a company is Realm Therapeutics PLC?

    Realm Therapeutics PLC has a market capitalization of £35.11 million.

    How can I contact Realm Therapeutics PLC?

    Realm Therapeutics PLC's mailing address is 508 Lapp Rd, MALVERN, PA 19355-1214, United States. The company can be reached via phone at +1-484-3212700.


    MarketBeat Community Rating for Realm Therapeutics PLC (RLM)

    Community Ranking:  2.3 out of 5 (star star)
    Outperform Votes:  34 (Vote Outperform)
    Underperform Votes:  40 (Vote Underperform)
    Total Votes:  74
    MarketBeat's community ratings are surveys of what our community members think about Realm Therapeutics PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

    Analyst Ratings

    Analysts' Consensus Rating for Realm Therapeutics PLC (LON:RLM)

      (How are Consensus Ratings Calculated?)
    Today30 Days Ago90 Days Ago180 Days Ago
    Consensus Rating: N/AN/AN/AN/A
    Consensus Rating Score: N/AN/AN/AN/A
    Ratings Breakdown: 0 Sell Rating(s)
    0 Hold Rating(s)
    0 Buy Rating(s)
    0 Strong Buy Rating(s)
    0 Sell Rating(s)
    0 Hold Rating(s)
    0 Buy Rating(s)
    0 Strong Buy Rating(s)
    0 Sell Rating(s)
    0 Hold Rating(s)
    0 Buy Rating(s)
    0 Strong Buy Rating(s)
    0 Sell Rating(s)
    0 Hold Rating(s)
    0 Buy Rating(s)
    0 Strong Buy Rating(s)
    Consensus Price Target: N/AN/AN/AN/A

    Consensus Price Target History for Realm Therapeutics PLC (LON:RLM)

    Price Target History for Realm Therapeutics PLC (LON:RLM)

    Analysts' Ratings History for Realm Therapeutics PLC (LON:RLM)

    Show:
    DateFirmActionRatingPrice TargetDetails
    9/22/2017N+1 SingerReiterated RatingcorporateView Rating Details
    (Data available from 11/24/2015 forward)

    Earnings

    Earnings History for Realm Therapeutics PLC (LON:RLM)


    No earnings announcements for this company have been tracked by MarketBeat.com

    Estimates

    Earnings Estimates for Realm Therapeutics PLC (LON:RLM)
    No earnings estimates for this company have been tracked by MarketBeat.com

    Dividends

    Dividend History for Realm Therapeutics PLC (LON:RLM)

    No dividend announcements for this company have been tracked by MarketBeat.com

    Insider Trades

    Insider Trading and Institutional Ownership History for Realm Therapeutics PLC (LON RLM)

    Insider Trades by Quarter for Realm Therapeutics PLC (LON:RLM)

    Insider Trades by Quarter for Realm Therapeutics PLC (LON RLM)

    Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
    12/20/2016Marella ThorellInsiderBuy50,000GBX 29£14,500
    9/22/2016Charles SpicerInsiderBuy17,482GBX 29£5,069.78
    3/29/2016Martin,AlexInsiderBuy100,000GBX 28£28,000
    10/14/2015Hegglin ,DanielInsiderBuy500,000GBX 18£90,000
    9/28/2015Spicer,CharlesInsiderBuy77,922GBX 19£14,805.18
    4/1/2015Charles SpicerInsiderBuy50,610GBX 32£16,195.20
    (Data available from 1/1/2013 forward)

    Headlines

    Latest Headlines for Realm Therapeutics PLC (LON RLM)

    Source:
    DateHeadline
    Realm Therapeutics Appoints Sandy Zweifach as Non-Executive Director and Non-Executive Directors Matthew Hammond and Daniel Hegglin Retire from the BoardRealm Therapeutics Appoints Sandy Zweifach as Non-Executive Director and Non-Executive Directors Matthew Hammond and Daniel Hegglin Retire from the Board
    finance.yahoo.com - November 18 at 11:24 AM
    Realm Therapeutics to Present at BIO-Europe® 2017Realm Therapeutics to Present at BIO-Europe® 2017
    finance.yahoo.com - November 2 at 8:19 AM
    Realm Presents Data at ACAAI Scientific Meeting - London South East (blog)Realm Presents Data at ACAAI Scientific Meeting - London South East (blog)
    www.lse.co.uk - October 31 at 8:47 AM
    Realm Therapeutics Presents Data Highlighting PR013s Efficacy Reducing Hyperemia and Pruritus Associated with ... - PR Newswire (press release)Realm Therapeutics Presents Data Highlighting PR013's Efficacy Reducing Hyperemia and Pruritus Associated with ... - PR Newswire (press release)
    www.prnewswire.com - October 31 at 8:47 AM
    Realm Therapeutics Presents Data Highlighting PR013s Efficacy Reducing Hyperemia and Pruritus Associated with Allergic Conjunctivitis at The American College of Allergy, Asthma, and Immunology (ACAAI) Scientific MeetingRealm Therapeutics Presents Data Highlighting PR013's Efficacy Reducing Hyperemia and Pruritus Associated with Allergic Conjunctivitis at The American College of Allergy, Asthma, and Immunology (ACAAI) Scientific Meeting
    finance.yahoo.com - October 31 at 8:47 AM
    Realm Therapeutics Raises GBP19.3 Million, Interim Loss Widens (ALLISS)Realm Therapeutics Raises GBP19.3 Million, Interim Loss Widens (ALLISS)
    www.morningstar.co.uk - September 23 at 2:52 AM
    Is There Now An Opportunity In Realm Therapeutics Plc (AIM:RLM)?Is There Now An Opportunity In Realm Therapeutics Plc (AIM:RLM)?
    finance.yahoo.com - September 22 at 4:45 PM
    Realm Therapeutics PLC (RLM) Rating Reiterated by N+1 SingerRealm Therapeutics PLC (RLM) Rating Reiterated by N+1 Singer
    www.americanbankingnews.com - September 22 at 2:36 PM
    Realm Therapeutics PLC (RLM) Given "corporate" Rating at N+1 SingerRealm Therapeutics PLC (RLM) Given "corporate" Rating at N+1 Singer
    www.americanbankingnews.com - September 11 at 10:10 AM
    Conference Presentation - London South East (registration) (blog)Conference Presentation - London South East (registration) (blog)
    www.lse.co.uk - September 9 at 7:57 AM
    Realm Therapeutics PLCs (LON:RLM) corporate Rating Reiterated at N+1 SingerRealm Therapeutics PLC's (LON:RLM) corporate Rating Reiterated at N+1 Singer
    www.americanbankingnews.com - July 9 at 7:30 AM
    Presentation at 2017 Marcum Microcap Conference - London South East (registration) (blog)Presentation at 2017 Marcum Microcap Conference - London South East (registration) (blog)
    www.lse.co.uk - June 16 at 9:23 AM
    Keith A. Goldan CPAKeith A. Goldan CPA
    www.bloomberg.com - March 7 at 7:26 PM
    Realm Therapeutics: FDA permits PR022 to Proceed to Phase 2 TrialRealm Therapeutics: FDA permits PR022 to Proceed to Phase 2 Trial
    www.finanznachrichten.de - March 2 at 12:52 AM

    Social Media

    Social activity is not available for this stock.

    Financials

    Financials are not available for this stock.

    Chart

    Realm Therapeutics PLC (LON RLM) Chart for Friday, November, 24, 2017
    Loading chart…

    This page was last updated on 11/24/2017 by MarketBeat.com Staff

    Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.